Subscribe to this RSS feed

EPP News

To be a child with EPP

03 Jan 2012
Read more...
Megan, 8, has erythropoietic protoporphyria (EPP), an absolute intolerance to light. After a very generous donation, watch her reactions to her new playground, a safe place for her to play outside during daylight hours.

Clinuvel announces Phase II US EPP results

29 Nov 2011
Read more...
In November Clinuvel released results from our first Phase II study of SCENESSE (afamelanotide) conducted in the USA. You can read the company's full release here along with comments from CEO, Dr Philippe Wolgen, on the blog. Press coverage: Australian Life Scientist | Biospectrum Asia | Pharmaceutical Business Review

Clinuvel Blog Posts

Inside Clinuvel: Rare diseases day 2013 - rare disea...

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Read More

Q&A: SCENESSE® successful in Phase IIa vitiligo...

We've just released the first results from our vitiligo program which you can view online here. Following their release, we expect a number...

Read More

Inside Clinuvel: Vitiligo and the “Michael Jackson...

I find vitiligo to be a fascinating, yet devastating disorder: almost overnight, patients see their skin colour erode and their identity...

Read More

Clinuvel Webcasts

What can vitiligo patients do? – Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

The future of vitiligo treatment – Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Vitiligo trials of SCENESSE® – Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now